Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Examining the Evolution of Treatment With Targeted Agents in Metastatic Breast Cancer

April 12th 2024

Anne Favret, MD discusses the evolution of treatment with endocrine-based combination therapies in HR-positive/HER2-negative metastatic breast cancer.

FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer

April 12th 2024

The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.

Dr Park on the Assessment of Robot-Assisted Nipple Sparing Mastectomy in Breast Cancer

April 12th 2024

Ko Un “Clara” Park, MD discusses the assessment of robot-assisted nipple sparing mastectomy in breast cancer.

Dr Cobain on Second- and Later-Line Treatment Options in HR+/HER2– Breast Cancer

April 12th 2024

Erin Frances Cobain, MD, on second-line treatment options for patients with HR-positive, HER2-negative metastatic breast cancer.

5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer

April 10th 2024

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide an in-depth analysis of the randomized phase III monarchE trial, which focused on Abemaciclib in high-risk early-stage HR+, HER2- breast cancer, offering insights into recurrence rates, progression-free survival, and distant disease-free survival outcomes for patients.

Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC

April 8th 2024

Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.

Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer

April 8th 2024

Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.

Dr Arteaga on CDK4/6 Inhibitor Resistance in ER+ Breast Cancer

April 3rd 2024

Carlos Arteaga, MD, discusses the resistance to CDK4/6 inhibitors in estrogen receptor–positive breast cancer.

NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer

April 3rd 2024

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, examine the NCCN guidelines compared to real-world evidence, particularly in the treatment of menopausal, pre-menopausal, and high-risk early-stage HR+/HER2- patients.

A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2- Positive Metastatic Breast Cancer With Brain Metastases (BMs) from DESTINY-Breast01, -02, and -03

April 2nd 2024

Sara Tolaney, MD, MPH, presents an exploratory pooled analysis of efficacy and safety data of trastuzumab deruxtecan vs comparator in patients with HER2-positive metastatic breast cancer and brain metastases from DESTINY-Breast01, -02, and -03.

FDA Accepts BLA for Datopotamab Deruxtecan for Pretreated HR+/HER2– Metastatic Breast Cancer

April 2nd 2024

The FDA has accepted a biologics license application for datopotamab deruxtecan in HR-positive, HER2-negative metastatic breast cancer.

Dr Mahtani on Addressing Unmet Needs in Breast Cancer

April 1st 2024

Reshma L. Mahtani, DO, discusses how attempts to address unmet needs in breast cancer have evolved over time.

UTD1 Receives FDA Orphan Drug Designation in Breast Cancer Brain Metastasis

April 1st 2024

Utidelone injectable has received FDA orphan drug designation for patients with breast cancer brain metastases.

The Breast Cancer Index Impacts Physicians’ Decision to Extend Endocrine Therapy for HR+ Early-Stage Disease

March 28th 2024

Incorporating the Breast Cancer Index test assay into practice affected clinicians’ decision to offer endocrine therapy in HR+ early-stage disease.

Exciting Data in the Treatment of HER2-low from SABCS 2023

March 28th 2024

Laura Spring, MD, and Manali Bhave, MD, highlight promising new systemic treatment options on the horizon for patients with metastatic breast cancer, including T-DM1 for HER2-low disease, the AKT inhibitor capivasertib, and novel endocrine therapies.

Sequencing Antibody-Drug Conjugates (ADCs) in HR+/HER2-Low Metastatic Breast Cancer

March 28th 2024

Laura Spring, MD, and Manali Bhave, MD, discuss sequencing approved antibody-drug conjugates, T-DM1 and sacituzumab govitecan, for hormone receptor-positive, HER2-low metastatic breast cancer after progression on chemotherapy.

Capivasertib/Fulvestrant Wins Approval in Japan for Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

March 27th 2024

Capivasertib plus fulvestrant has been approved in Japan for pretreated, PIK3CA-, AKT1-, or PTEN-altered, HR-positive, HER2-negative breast cancer.

HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification

March 27th 2024

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, discuss the biological and pathological risk factors influencing breast cancer development, treatment, and risk stratification.

Dr Dizon on the Prevalence of Sexual Challenges in Patients With Breast Cancer

March 26th 2024

Don S. Dizon, MD, on the prevalence of sexual complications in patients with breast cancer.

Clinical Benefits With Neratinib in HER2+ Early Breast Cancer

March 25th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.